Thalassaemia care is advancing fast, from gene therapies to AI diagnostics, but access and prevention still lag behind. Hear from the authors of The Lancet Haematology's "Thalassaemia revisited: from health burden to breakthroughs" Series, produced with The Lancet Regional Health – Southeast Asia, on epidemiology across Asia, what's working in prevention, the real barriers to gene therapy access, and what's next for hydroxyurea, regional manufacturing, and AI in patient care.

Click here to visit the series Hub page: 

www.thelancet.com/series-do/thalassaemia

Or read the full articles from:

The Lancet Regional Heath Southeast Asia:  https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(26)00148-4/fulltext and https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(26)00095-8/fulltext

The Lancet Haematology: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00173-0/fulltext and https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00197-3/fulltext

The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering. 

Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

Podcast editing: Matteo Simonetti

Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

Find the best science for better lives at www.thelancet.com

Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Podden och tillhörande omslagsbild på den här sidan tillhör The Lancet Group. Innehållet i podden är skapat av The Lancet Group och inte av, eller tillsammans med, Poddtoppen.